Cambridge Healthtech Institute’s Ninth Annual

Cancer Molecular Markers

Guiding Cancer Management

March 7 – 9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference


Preliminary Agenda


Liquid Biopsy: Expectations and Required Steps to Bring It into Clinical Practice

Klaus Pantel, M.D., Professor and Founding Director, Institute of Tumor Biology, University, Medical Center Hamburg-Eppendorf

Talk Title to be Announced

Howard I. Scher, M.D., Chief, Genitourinary Oncology & Solid Tumor Medicine, Memorial Sloan Kettering Cancer Center

THE NEXT THING IN CIRCULATING BIOMARKERS: Beyond Characterization and Enumeration of CTCs

FEATURED PRESENTATION: Circulating Pancreas Cells to Stratify Risk in Patients at High Risk For Developing Pancreatic Cancer and RNA Editing Using NGS

Andrew D. Rhim, M.D., Assistant Professor, Internal Medicine, Division of Gastroenterology, University of Michigan

Novel Biomarkers to Increase Efficiency of Detecting CTCs and Associated Immune Cells

Lidia C. Sambucetti, Ph.D., Senior Program Director, Biosciences Division, SRI International

Platelet Cloaking, Cancer Cells and CTCs: Lessons for the Metastatic Cascade

John O'Leary, M.D., Ph.D., Chair, Pathology, Trinity College Dublin; Director, Pathology, Coombe Women and Infants University Hospital; Consultant, Pathologist, St. James’s Hospital; Principal Investigator, Biomedical Diagnostics Institute (BDI)


Tissue-Based Assessment of PD-L1 and Other Tumor Microenvironmental Factors in Melanoma Specimens

Janis M. Taube, M.D., MSc, Director, Dermatopathology; Assistant Professor, Dermatology and Pathology, Johns Hopkins

Tissue-Based Analyses to Guide Immunotherapy for Lymphoma

Scott Rodig, M.D., Ph.D., Hematopathologist, Pathology, Brigham and Women’s Hospital

Immune Profiling of Lung Cancer Tissue Specimens

Ignasio I. Wistuba, M.D., Department Chair, Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center; Anderson Clinical Faculty Chair, Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center

Beyond PD-L1: Other Potential Companion Diagnostic Tests for Immune Checkpoint Therapy

David L. Rimm, M.D., Ph.D., Professor, Pathology, Yale University


Circulating Tumor Cells and Mouse Models of Serous Ovarian Cancer

Victoria Bae-Jump, M.D., Ph.D., Associate Professor, Division of Gynecologic Oncology, University of North Carolina

Orthotopic Mouse Models of Cancer and GFP Labeling for the Study of Circulating Tumor Cells

Robert M. Hoffman, Ph.D., President, AntiCancer, Inc.; Professor, Surgery, University of California, San Diego


Early Pancreatic Markers, Biomarkers for Exosome Isolation

Raghu Kalluri, M.D., Ph.D., Professor & Chair, Cancer Biology, MD Anderson Cancer Center

Isolating Circulating Biomarkers: Compare and Contrast cfDNA, CTCs and Exosomes

Steven A. Soper, Ph.D., Professor, Biomedical Engineering & Chemistry; Associate Editor, Analyst; Director, Center for BioModular Multiscale Systems, University of North Carolina

Why Do Cancer Cells Move?

Daniel Irimia, M.D., Ph.D., Assistant Professor, Division of Surgery, Science & Bioengineering, Massachusetts General Hospital and Harvard Medical School; Associate Director, BioMEMS Resource Center

Extracellular Vesicles as Couriers of Cancer Information

Xandra O. Breakefield, Ph.D., Professor, Neurology, Harvard Medical School; Geneticist, Department of Neurology and Radiology, Massachusetts General Hospital


Tethered Lipoplex Nanoparticle (TLN) Biochips for Extracellular Vesicles Based Early Disease Diagnosis and Prognosis

L. James Lee, Ph.D., Helen C. Kurtz Chair, Chemical & Biomolecular Engineering, Ohio State University

PROPAGATING CELLS: CTCs as Early Guide for Treatment Response Prior to Imaging

Tumorigenicity and Genetic Profiling of Circulating Tumor Cells in Small-Cell Lung Cancer

Kristopher Frese, Ph.D., Postdoctoral Fellow, University of Manchester

Antibody-Free Capture of Tumor Cells from Blood and Novel CTC-Targeting Therapeutics

Michael R. King, Ph.D., Daljit S. and Elaine Sarkaria Professor of Biomedical Engineering, Meinig School of Biomedical Engineering, Cornell University

Conditional Reprogramming Rapidly and Efficiently Generates Normal and Tumor Cell Cultures

Richard Schlegel, M.D., Ph.D., Professor and Oscar B. Hunter Chair, Pathology; Director, Center for Cell Reprogramming, Georgetown University Medical School

Premier Sponsors:  

Bina Technologies




Jackson Laboratory - small logo 


 Precision for Medicine 


Silicon Biosystems

Thomson Reuters-Large